JMP Securities analyst Jason Butler reiterated a Buy rating on Halozyme (NASDAQ:HALO) Therapeutics on Friday, setting a price target of $55, which is approximately 72.85% above the present share price of $31.82.
Butler expects Halozyme Therapeutics to post earnings per share (EPS) of $1.53 for the fourth quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Halozyme, with an average price target of $53.13.
The analysts price targets range from a high of $62 to a low of $46.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $115.83 million and a net profit of $75.59 million. The company's market cap is $4.48 billion.
According to TipRanks.com, JMP Securities analyst Jason Butler is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 0.9% and a 39.94% success rate.
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.